Future Cardia
- Company typePrivate
- Founded2021
- HeadquartersHouston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Future Cardia firmographics
Firmographics- Name
- Future Cardia
- Legal name
- Future Cardia
- Website
- https://futurecardia.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Future Cardia industry classification
Industry- Product category
- Implantable Cardiac Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
- akta.pro secondary industry
- Electrophysiology (Heart Rhythm) (HLAKABAC)
Keywords
Where Future Cardia is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Future Cardia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Implantable Cardiac Monitoring Device Sales: Pre-commercial stage. The company is developing an implantable cardiac monitoring device awaiting FDA approval. Revenue will be generated through device sales to healthcare providers and hospitals. The device is positioned as a Class II, 510K device with existing insurance coverage, facilitating reimbursement through healthcare systems.
- Remote Monitoring Platform Integration: Partnership with Artella Solutions integrates their remote cardiac monitoring platform with Future Cardia's device, potentially enabling data-driven services and monitoring fees as part of comprehensive cardiac care solutions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Device pricing not disclosed |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Future Cardia product offering
Product offeringCore offering
Future Cardia is developing a single product — the "Voice of the Heart" Cardiac Monitoring System — an implantable, under-the-skin Class II 510(k) cardiac monitor. The device combines four sensors (ECG for heart rhythms, PCG for heart sounds, SCG for cardiac pressure, and an accelerometer for activity) and is implanted in a 2-minute office procedure with a 2-year battery, providing long-term continuous cardiac data for arrhythmia and heart failure patients. It is intended for sale to hospitals and healthcare providers and is currently awaiting FDA approval.
Differentiator
Problem solved
Functional benefit
Products and services
- Voice of the Heart Cardiac Monitoring System An implantable, under-the-skin Class II 510(k) cardiac monitoring device combining ECG (heart rhythms), PCG (heart sounds), SCG (cardiac pressure), and accelerometer (activity) sensors. Implanted via a 2-minute office procedure with a 2-year battery, providing continuous long-term cardiac data for arrhythmia and heart failure patients. Sold to hospitals, cardiac care centers, and healthcare providers; supported by existing insurance reimbursement and integration with Artella Solutions' remote monitoring platform.
Quantifiable outcome
- 2-year battery life for long-term monitoring
- +2 more outcomes
Companies that use Future Cardia
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Future Cardia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
Future Cardia partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Artella SolutionscoreFuture Cardia has expanded its collaboration with Artella Solutions, a remote cardiac monitoring company. The partnership focuses on integrating Artella's monitoring platform with Future Cardia's implantable cardiac monitoring device to enhance data transfer and clinical workflows. This integration aims to provide comprehensive cardiac care solutions.
- StartEngine Primary, LLCminorReg A+ offering distribution partner for equity crowdfunding. Member FINRA/SIPC. Provides platform for retail investor participation in funding rounds.
Scale indicators5 records
Future Cardia competitors and assessment
Company assessmentEmerging players
- Cala Health: Developer of wearable neuromodulation therapy for essential tremor and other conditions, with similar early-stage Class II medical device commercialization dynamics. Less direct overlap but comparable as a small medtech with KOL-driven hospital adoption.
- Eko Health: Developer of AI-enabled digital stethoscopes with ECG and heart sound (PCG) capabilities. Comparable in combining ECG + PCG sensor modalities and applying them to cardiac diagnostics, though in a non-implant form factor.
- AliveCor: Maker of KardiaMobile personal ECG devices and KardiaNet remote monitoring services. Comparable as an AI-driven ambulatory cardiac monitoring company with recurring monitoring revenue, though focused on consumer/short-term monitoring.
- Vectorious Medical Technologies: Developer of an implantable left-atrial pressure sensor for heart failure monitoring. Comparable as an early-stage implantable cardiac monitoring startup targeting the same heart failure population and electrophysiology/cardiologist buyers.
- Preventice Solutions: Remote cardiac monitoring services company offering BodyGuardian wearable monitors (acquired by Boston Scientific in 2021). Adjacent/emerging competitor in ambulatory cardiac monitoring workflows overlapping with Future Cardia's Artella partnership.
Broad incumbents
- Medtronic: Global medtech incumbent with the LINQ insertable cardiac monitor (ICM), the dominant product in implantable cardiac rhythm monitoring. Directly comparable category leader Future Cardia will compete with on electrophysiology hospital sales.
- Boston Scientific: Major cardiac device company with an insertable cardiac monitor and a strong electrophysiology portfolio. Competes for the same hospital and EP lab customers Future Cardia is targeting.
- Abbott: Broad incumbent offering the Confirm Rx insertable cardiac monitor plus CardioMEMS for heart failure monitoring. Comparable as a multi-modality cardiac monitoring incumbent with deep electrophysiology relationships.
Direct peers
- iRhythm Technologies: Developer of the Zio long-term cardiac monitoring patch, a competing ambulatory cardiac monitoring solution. Highly comparable as an outpatient cardiac rhythm monitoring company competing for the same electrophysiology prescribing decisions.
- Biotronik: European cardiovascular device manufacturer with an insertable cardiac monitor (BioMonitor) in the same Class II category as Future Cardia's device. Closely comparable on product type and hospital/cardiologist customer base.
Market position
Customer concentration
Future Cardia social profiles
Digital presenceFuture Cardia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Future Cardia leadership team
Management profileNumber of profiles
Profiles4 records
Future Cardia funding detail
Funding detailFunding overview
Funding rounds7 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Future Cardia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Future Cardia
What does Future Cardia do?
Future Cardia is developing a single product — the "Voice of the Heart" Cardiac Monitoring System — an implantable, under-the-skin Class II 510(k) cardiac monitor. The device combines four sensors (ECG for heart rhythms, PCG for heart sounds, SCG for cardiac pressure, and an accelerometer for activity) and is implanted in a 2-minute office procedure with a 2-year battery, providing long-term continuous cardiac data for arrhythmia and heart failure patients. It is intended for sale to hospitals and healthcare providers and is currently awaiting FDA approval.
Is Future Cardia a public or private company?
Future Cardia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Future Cardia founded?
Future Cardia was founded in 2021. It employs 1 to 10 people.
Where is Future Cardia based?
Future Cardia is headquartered in Houston, United States, in the North America region.
How does Future Cardia make money?
Two revenue lines are on record. Implantable Cardiac Monitoring Device Sales are the primary driver. The others are remote Monitoring Platform Integration.
Who are Future Cardia's main competitors?
Emerging players on record are Cala Health, Eko Health, AliveCor, Vectorious Medical Technologies and Preventice Solutions. Broad incumbents are Medtronic, Boston Scientific and Abbott. Direct peers are iRhythm Technologies and Biotronik.
Does Future Cardia have an API?
No public API is recorded for Future Cardia.
What industry is Future Cardia in?
Future Cardia's product category is Implantable Cardiac Monitoring Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3845.